TL
tsung-hsien lee
Chung Shan Medical University
Taichung, Taiwan
About this Research Topic
This Research Topic is closed for submissions.
Background
Given the success of Research Topic Recent Advances in Ovarian Stimulation and the rapidly evolving subject area, we are pleased to announce the launch of Volume II.
Controlled ovarian stimulation (COS) is a pivotal process in assisted reproductive technology, specifically in in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). This dynamic field seeks to optimize the super-physiological cycle to harvest multiple oocytes by tailoring treatment protocols to the individual nuances of each patient, considering their clinical history, age, and ovarian reserves. Despite the established algorithms, there remains a consistent necessity to refine and enhance these methods to boost treatment success rates. Contemporary research continues to evolve, aiming to decipher the complexities of each of the five critical sequential steps involved in IVF/ICSI: stimulation, ovulation trigger, egg retrieval, laboratory procedures, and embryo transfer.
This Research Topic aims to deliver a comprehensive update on COS by encapsulating both the historical milestones and the cutting-edge innovations currently under exploration. It seeks to foster a deeper understanding of the nuances and evolving techniques that characterize the current landscape of ovarian stimulation, highlighting the intersection between traditional practices and innovative approaches that suggest promising avenues for enhanced efficacy in fertility treatments.
To gather further insights into the nuanced application of COS techniques and their outcomes, we welcome Original Research articles and Reviews addressing, but not limited to, the following themes:
o Pre-treatment therapies such as oral contraceptives, progestogens, oestrogen, GnRH antagonists, and androgen supplementation.
o Diverse protocols for controlled ovarian stimulation including conventional, mild, and modified natural cycles.
o Advanced regimens for final oocyte maturation involving hCG, GnRH agonist, dual trigger, and kisspeptin.
o Variance in Luteal phase support agents, focusing on progesterone, dydrogesterone, oestradiol, and alternative routes of administration.
Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
